Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 36, 2018 (suppl; abstr LBA4)
Pembrolizumab als tweedelijnsbehandeling bij gevorderd urotheelcarcinoom
mrt 2017 | Uro-oncologie